Acathinol Memantine, pills 20mg, 28pcs

Composition

1 coated tablet contains:

Active ingredient:

memantine gilrochloride 10 mg;

Auxiliary substances:

lactose,

MCC,

colloidal silicon dioxide,

talc,

magnesium stearate,

shell:

methacrylic acid copolymer,

sodium lauryl sulfate,

talc.

Pharmacological action

Pharmacodynamics

Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system. Regulates ion transport, blocks calcium channels, normalizes the membrane potential, and improves the process of nerve impulse transmission. Improves cognitive processes, increases daily activity.

Pharmacokinetics

After oral use, Acatinol Memantine is rapidly and completely absorbed. The maximum concentration in the blood plasma is reached within 2-6 hours. No accumulation of the drug was observed in normal renal function. Elimination proceeds in two phases. The elimination half-life is 4-9 hours in the first phase and 40-65 hours in the second phase. It is excreted in the urine.

Indications

Alzheimer’s type dementia, vascular dementia, mixed dementia of all degrees of severity.

Contraindications

• individual hypersensitivity to the drug Akatinol Memantine;
• severe renal dysfunction;
• pregnancy;
• breastfeeding;
• children under 18 years of age (due to insufficient data).

With caution:

• thyrotoxicosis;
• epilepsy;
• convulsions (including in the anamnesis);
• myocardial infarction;
• heart failure.

Side effects

Adverse reactions are classified according to clinical manifestations (according to the lesion of certain organ systems) and frequency of occurrence:

From the body as a whole-common side effects

Often Headache

Rarely Fatigue

Infections Rarely Fungal infections

Mental disorders Often Drowsiness

Rarely Confusion

Rarely Hallucinations

Frequency not established

Psychotic reactions

Disorders of the cardiovascular system

Rarely Hypertension

Rarely Venous thrombosis / thromboembolism

Gastrointestinal disorders Often Constipation

Rarely Nausea, vomiting

Frequency not established Pancreatitis

Central and peripheral nervous system disorders

Often Dizziness

Rarely Gait disorder

Very rarely, Convulsive

Hallucinations have been observed, mainly in patients with Alzheimer’s disease at the stage of severe dementia.

There are isolated reports of these adverse reactions occurring when the drug is used in clinical practice (data obtained after the drug became commercially available).

Interaction

When used concomitantly with L-dopa preparations, dopamine agonists, and anticholinergic agents, the effect of the latter may be enhanced.

When used concomitantly with barbiturates, neuroleptics, the effect of the latter may decrease.

When used together, it can change (increase or decrease) the effect of dantrolene or baclofen, so the dosage of drugs should be selected individually. Concomitant use with amantadine, ketamine, and dexamethorphan should be avoided.

It is possible to increase plasma levels of cimetidine, procainamide, kinidine, kinine and nicotine when taken simultaneously with memantine. It is possible to reduce the level of hydrochlorothiazide when taken simultaneously with memantine.

How to take, course of use and dosage

Inside, while eating. The dosage regimen is set individually. It is recommended to start treatment with the minimum effective dose.

Adults with dementia during the 1st week of therapy — at a dose of 5 mg / day, the 2nd week-at a dose of 10 mg/day, the 3rd week-at a dose of 15-20 mg/day. If necessary, a further weekly dose increase of 10 mg is possible until the daily dose of 30 mg is reached.

The optimal dose is achieved gradually, with an increase in the dose every week.

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.

Special instructions

With caution prescribed for epilepsy, patients with thyrotoxicosis. The optimal dose is achieved gradually, with a weekly increase.

Patients with moderate to severe Alzheimer’s disease usually have impaired ability to drive vehicles and manage complex mechanisms.

In addition, memantine can cause changes in the reaction rate, so patients receiving outpatient treatment should take special care when driving vehicles or operating mechanisms.

Form of production

Film-coated tablets

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

4 years

Active ingredient

Memantine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Alzheimer’s disease, Stroke Effects, Acquired Dementia, Concussion and other traumatic brain injuries, Alcoholism